Spero Therapeutics, Inc. SPRO

Set alert

Price alert · SPRO

All alert types
1.04 USD -0.02 -1.89%

At close

1.07 +0.03 +2.88%

Pre-market · Nov 3, 6:03 AM ET

Bid
1.04 × 3
Ask
1.05 × 3
1.03 Day range 1.10
1.03 52-week range 3.08
YTD
-55.36%
1 year
-57.20%
Open
1.10
Prev close
1.06
Mkt cap
60.56M
Vol
433.56K
Avg vol
600.50K
EPS
0.14
P/E
7.43
Div yield
0.00%
More statistics
Low
1.03
High
1.10
Forward P/E
-0.83
Beta
0.63
Short ratio
2.08
Inst. own
23.05%
Dividend
0.00
Ex-div date
Earnings
Aug 5, 2024
50-d avg
1.20
200-d avg
1.38
1y target
5.00

3M chart

Chart tools
Interval

Signals (24)
NameDateAgo
MACD: Sell SignalOct 30, 20263 days ago
MACD: Buy SignalOct 28, 20265 days ago
MACD: Sell SignalOct 23, 20261 week ago
SMA: BearishOct 21, 20261 week ago
SMA: BullishOct 20, 20261 week ago
SMA: BullishOct 20, 20261 week ago
MACD: Buy SignalOct 20, 20261 week ago
MACD: Sell SignalOct 13, 20262 weeks ago
SMA: BearishOct 12, 20263 weeks ago
SMA: BullishOct 9, 20263 weeks ago
MACD: Buy SignalOct 9, 20263 weeks ago
MACD: Sell SignalOct 8, 20263 weeks ago
SMA: BearishOct 2, 20261 month ago
SMA: BearishOct 2, 20261 month ago
SMA: BullishSep 30, 20261 month ago
SMA: BearishSep 28, 20261 month ago
SMA: BearishSep 28, 20261 month ago
SMA: BullishSep 22, 20261 month ago
SMA: BullishSep 22, 20261 month ago
RSI: OversoldSep 16, 20261 month ago

Newest 20 of 24.

Analyst view

Consensus: buy

Buy
Price target (mean) 5.00
Ratings (0m) 4 2 buy · 2 hold · 0 sell
  • Strong buy1
  • Buy1
  • Hold2
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 4
  • 1 month ago 4
  • 2 months ago 4

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

SPRO analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.40667-0.60 – -0.270.96-142.4%4.13M-94.4%3
Next quarter-0.265-0.33 – -0.20-0.24-10.4%11.00M+18.7%2
Current year-1.29-1.48 – -1.170.5305-343.8%36.94M-64.4%3
Next year-0.91667-1.17 – -0.74-1.29+29.1%20.00M-45.9%3

Upgrades and downgrades

The latest rating changes

SPRO analyst upgrades and downgrades
DateFirmActionFromTo
Dec 20, 2024Evercore ISI GroupDowngradeOutperformIn-Line
Dec 2, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 18, 2024TD CowenDowngradeBuyHold
Nov 15, 2024Cantor FitzgeraldReiterated—Overweight
Nov 4, 2024HC Wainwright & Co.MaintainedBuyBuy
Oct 3, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 6, 2024TD CowenUpgradeHoldBuy
Aug 6, 2024Cantor FitzgeraldReiterated—Overweight
Aug 6, 2024HC Wainwright & Co.ReiteratedBuyBuy
May 16, 2024HC Wainwright & Co.ReiteratedBuyBuy
Apr 4, 2024Cantor FitzgeraldReiterated—Overweight
Mar 18, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 14, 2023HC Wainwright & Co.ReiteratedBuyBuy
Sep 5, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 14, 2023HC Wainwright & Co.MaintainedBuyBuy
Aug 1, 2023HC Wainwright & Co.ReiteratedBuyBuy
Jul 20, 2023HC Wainwright & Co.ReiteratedBuyBuy
Apr 10, 2023HC Wainwright & Co.Reiterated—Buy
Sep 26, 2022HC Wainwright & Co.Maintained—Buy
Sep 23, 2022Evercore ISI GroupUpgradeIn-LineOutperform
Aug 15, 2022HC Wainwright & Co.Maintained—Buy
May 23, 2022HC Wainwright & Co.Maintained—Buy
May 20, 2022BerenbergDowngradeBuyHold
May 17, 2022Cantor FitzgeraldMaintained—Overweight
May 4, 2022Cowen & Co.DowngradeOutperformMarket Perform
May 4, 2022Evercore ISI GroupDowngradeOutperformIn-Line
Apr 18, 2022HC Wainwright & Co.Maintained—Buy
Mar 21, 2022HC Wainwright & Co.Maintained—Buy
Oct 1, 2021OppenheimerDowngradeOutperformPerform
Jan 22, 2021HC Wainwright & Co.Maintained—Buy